التفاصيل البيبلوغرافية
| العنوان: |
Serum pepsinogen 1 and anti‐Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males. |
| المؤلفون: |
Song, M., Camargo, M. C., Weinstein, S. J., Murphy, G., Freedman, N. D., Koshiol, J., Stolzenberg‐Solomon, R. Z., Abnet, C. C., Männistö, S., Albanes, D., Rabkin, C. S. |
| المصدر: |
Alimentary Pharmacology & Therapeutics; Feb2018, Vol. 47 Issue 4, p494-503, 10p, 5 Charts, 1 Graph |
| مصطلحات موضوعية: |
BLOOD serum analysis, PEPSINOGEN, HELICOBACTER pylori, IMMUNOGLOBULIN G, STOMACH cancer risk factors, FINNS, DISEASES |
| مستخلص: |
Summary: Background: Serum pepsinogen 1 (SPG1) and anti‐Helicobacter pylori serology have been used for gastric risk stratification in Asia. Aim: To assess utility of these markers in a Western population. Methods: SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention Study. We used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI) for low SPG1 (<25 μg/L). In a subset (n = 3555) with anti‐H. pylori serology, these markers jointly defined the following: Group A (H. pylori[−], SPG1[normal]; reference group), Group B (H. pylori[+], SPG1[normal]), Group C (H. pylori[+], SPG1[low]) and Group D (H. pylori[−], SPG1[low]). Odds ratios (ORs) and 95% CI were calculated using multivariate logistic regression. Results: There were 329 gastric cancers diagnosed an average of 13.9 years after baseline. Pre‐diagnostic low SPG1 was significantly associated with increased gastric cancer risk (HR 2.68, 95% CI 1.99‐3.61). Among subjects with both SPG1 and H. pylori serology, groups B, C and D had increased gastric cancer ORs (95% CI) of 1.79 (1.21‐2.64), 3.85 (2.36‐6.28) and 6.35 (2.20‐18.34), respectively. CagA seropositives had significantly higher ORs than CagA seronegatives within group B (Pheterogeneity = 0.01). For groups B and C, repeat SPG1 level at 3 years did not further stratify gastric cancer risk. Conclusions: Low SPG1 was associated with increased gastric cancer risk in our large Finnish cohort. A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk. [ABSTRACT FROM AUTHOR] |
|
Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder